These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1817 related items for PubMed ID: 29420164

  • 21. Apalutamide and its use in the treatment of prostate cancer.
    Borno HT, Small EJ.
    Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
    [Abstract] [Full Text] [Related]

  • 22. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
    Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ.
    JAMA Oncol; 2021 Jul 01; 7(7):1005-1014. PubMed ID: 34081076
    [Abstract] [Full Text] [Related]

  • 23. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ.
    Clin Cancer Res; 2021 Aug 15; 27(16):4539-4548. PubMed ID: 34112710
    [Abstract] [Full Text] [Related]

  • 24. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2022 Jan 15; 39(1):518-531. PubMed ID: 34797506
    [Abstract] [Full Text] [Related]

  • 25. Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
    Chung BH, Huang J, Ye ZQ, He DL, Uemura H, Arai G, Kim CS, Zhang YY, Koroki Y, Jeong S, Mundle S, Triantos S, McCarthy S, Chi KN, Ye DW.
    Asian J Androl; 2022 Jan 15; 24(2):161-166. PubMed ID: 34259202
    [Abstract] [Full Text] [Related]

  • 26. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
    Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, Agarwal N.
    Eur Urol Oncol; 2024 Aug 15; 7(4):844-852. PubMed ID: 38072759
    [Abstract] [Full Text] [Related]

  • 27. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
    Tsuchiya T, Imanaka K, Iwaki Y, Oyama R, Hashine K, Yamaguchi A, Uemura H.
    Int J Clin Oncol; 2019 Dec 15; 24(12):1596-1604. PubMed ID: 31446511
    [Abstract] [Full Text] [Related]

  • 28. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 15; 37(1):501-511. PubMed ID: 31813086
    [Abstract] [Full Text] [Related]

  • 29. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
    Al-Salama ZT.
    Drugs; 2019 Sep 15; 79(14):1591-1598. PubMed ID: 31489589
    [Abstract] [Full Text] [Related]

  • 30. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators.
    N Engl J Med; 2020 Sep 10; 383(11):1040-1049. PubMed ID: 32905676
    [Abstract] [Full Text] [Related]

  • 31. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
    Hegele A, Häußermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, Ludwig M, Huwe P, Maywurm M, Bartsch-Polle A, Weber J, Thiemer M, Varughese D.
    J Cancer Res Clin Oncol; 2024 Sep 09; 150(9):414. PubMed ID: 39249593
    [Abstract] [Full Text] [Related]

  • 32. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Tombal B, Sternberg CN, Hussain M, Ganguli A, Li Y, Sandin R, Bhadauria H, Oh M, Saad F.
    ESMO Open; 2022 Jun 09; 7(3):100510. PubMed ID: 35714477
    [Abstract] [Full Text] [Related]

  • 33. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
    Uemura H, Arai G, Uemura H, Suzuki H, Aoyama J, Hatayama T, Ito M, Lefresne F, McCarthy S, Mundle S, He J, Chi KN.
    Int J Urol; 2022 Jun 09; 29(6):533-540. PubMed ID: 35293030
    [Abstract] [Full Text] [Related]

  • 34. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
    Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR.
    Ann Oncol; 2019 Nov 01; 30(11):1813-1820. PubMed ID: 31560066
    [Abstract] [Full Text] [Related]

  • 35. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R, ELM-PC 4 investigators.
    Lancet Oncol; 2015 Mar 01; 16(3):338-48. PubMed ID: 25701170
    [Abstract] [Full Text] [Related]

  • 36. [Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program].
    Spiegelhalder P, Bögemann M.
    Aktuelle Urol; 2022 Feb 01; 53(1):60-63. PubMed ID: 33882583
    [Abstract] [Full Text] [Related]

  • 37. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
    Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, Smith A, Uemura H.
    BMC Urol; 2020 Sep 02; 20(1):139. PubMed ID: 32878613
    [Abstract] [Full Text] [Related]

  • 38. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
    Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN.
    Ann Oncol; 2023 May 02; 34(5):477-485. PubMed ID: 36858151
    [Abstract] [Full Text] [Related]

  • 39. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 02; 37(1):512-526. PubMed ID: 31813087
    [Abstract] [Full Text] [Related]

  • 40. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW.
    Curr Treat Options Oncol; 2019 Feb 11; 20(2):14. PubMed ID: 30741354
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 91.